Research Library Compound Research
CJC-1295 No DAC is a growth hormone–releasing hormone analog used in preclinical research to examine receptor signaling, pulsatile endocrine models, and the analytical variables that distinguish shorter-acting constructs from albumin-binding derivatives.
For research use only. Not for human or veterinary use. This resource discusses experimental context and analytical documentation; it does not provide dosing, administration, or therapeutic guidance.
Overview
CJC-1295 No DAC is commonly used to describe a modified GHRH sequence without the drug affinity complex associated with longer-duration albumin binding. That distinction matters because “CJC-1295” is sometimes used imprecisely across catalogs and research discussions. A defensible study should identify the exact material, sequence, strength, batch, and analytical record rather than infer identity from a shortened name.
For a direct terminology and design comparison, review CJC-1295 No DAC vs DAC. Researchers evaluating a second secretagogue pathway can also consult CJC-1295 No DAC vs Ipamorelin.
Research context
GHRH analog research focuses on ligand interaction with the GHRH receptor and the downstream signaling conditions used to characterize growth-hormone release in controlled models. Published work on modified GHRH analogs illustrates how amino-acid substitutions and half-life extension strategies can alter experimental exposure and observed response. Those findings should not be transferred automatically between DAC and non-DAC materials.
Model selection, sampling timing, baseline endocrine variability, assay sensitivity, and comparator choice can materially affect interpretation. Where CJC-1295 No DAC is studied alongside ipamorelin or another growth-hormone secretagogue, each compound should be treated as a distinct experimental variable. A combination does not eliminate the need for single-material controls.
Analytical verification
A chromatographic purity percentage describes the relative area of detected components under a specified method; it does not independently establish molecular identity. Identity evidence may require mass-based analysis or another orthogonal method. Review purity vs identity in peptide analysis for the distinction.
When reviewing CJC-1295 No DAC documentation, confirm that the certificate connects to the physical batch through a lot or batch identifier. Check the stated sample name, nominal strength, analytical method, result, and testing date. A certificate for a different sequence, DAC form, or unmatched lot should not be treated as evidence for the material under study.
Study-design considerations
- Material definition: record the full compound designation and whether DAC is absent.
- Batch traceability: connect the vial, lot identifier, and certificate before use.
- Controls: include vehicle, single-material, and appropriate comparator conditions.
- Sampling plan: align collection timing with the specific experimental question.
- Evidence boundary: separate observations in a defined model from broader biological or clinical conclusions.
Research documentation
Not Labs separates educational context from batch-level records. The current catalog listing for CJC-1295 No DAC research peptide provides available strengths and the applicable product documentation path. For combination-oriented catalog research, see the GH Release Bundle.
Before relying on any record, use the peptide COA review guide and the COA red-flags checklist to verify that the method, result, and batch connection are clear.
Evidence and limitations
Peer-reviewed research on GHRH analogs provides useful mechanistic and pharmacokinetic context, including studies indexed under PMID 15817669, 16352683, and 17018654. However, differences in sequence, formulation, model, exposure, and endpoint design limit direct comparison. Conclusions should remain bounded to the material and conditions actually tested.